Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCMYM802 in Mesothelin-positive Advanced Solid Tumors
NCT06256055Phase 1Recruiting
- Sponsor
- UTC Therapeutics
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UCMYM802 in malignant mesothelioma, pancreatic cancer (PC), biliary tract cancer (BTC) and 8 more, sponsored by UTC Therapeutics. Primary endpoints: Treatment Emergent Adverse Event at 2 years, Treatment Related Adverse Event at 2 years and 2 more. Started Mar 2024; status: recruiting.
02
Drugs
UCMYM802
03
Conditions
malignant mesotheliomapancreatic cancer (PC)biliary tract cancer (BTC)lung cancerovarian cancer
Beyond the preview
Go deeper on NCT06256055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06256055.